1. Economic burden assessment for the management of asthma patients at Mexico's National Institute for Respiratory Diseases.
- Author
-
Cano-Salas, María del Carmen, Luis Miguel-Reyes, José, Sánchez-Trejo, Karen, del Carmen López-Estrada, Erika, Salas-Hernández, Jorge, Arroyo-Rojas, Monserrat Evelia, Castañeda-Valdivia, Mauricio, Escobar-Preciado, Monserrat, Guzmán-Vázquez, Silvia, Ricardo García-García, Sergio, and Soto-Molina, Herman
- Subjects
- *
MEDICAL research , *ASTHMA treatment , *ASTHMATICS , *RESPIRATORY diseases - Abstract
Objective: Determine the annual economic burden of the disease from an institutional perspective and based on GINA's recommended classification in a retrospective cohort of adults treated at Instituto Nacional de Enfermedades Respiratorias (INER) of Mexico City. Methods: A retrospective, longitudinal observational study comprised by data from 247 female asthma patients, annual direct costs were estimated including: visits, laboratory tests, pharmacological treatment and management of crisis or exacerbations, to determine the annual burden of the disease from an institutional perspective and according to Global Initiative for Asthma classification. Results: The average annual cost was $43,813.92, which increased in relation to the need of inhaled corticosteroids and long-acting beta agonists dosage increase. The average doctor's appointment cost was $2,004.57, $982.82 for crisis management and $2,645.95 for laboratory testing. Pharmacological treatment represented the main economic burden with an annual average cost of $38,180.58. Conclusions: The results highlight an economic burden of asthma estimated at an annual cost per patient of $43,813.92 MXN (SD=93,348.85) in the context of the third level of care in the Mexican public health system. The asthma severity and treatments such as biologics were the main factors that increased direct costs of care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF